擘画“十五五”：深化医改、赋能创新，锚定医药发展新航向

Core Insights - The article discusses the strategic opportunities in China's pharmaceutical sector as it transitions from the "14th Five-Year Plan" to the "15th Five-Year Plan," emphasizing the integration of health initiatives and global biopharmaceutical competition [1][2] Industry Development - The "15th Five-Year Plan" outlines a health-first development strategy, focusing on enhancing public health capabilities, promoting hierarchical diagnosis and treatment, and supporting the development of innovative drugs and medical devices [2][3] - The plan aims to bind pharmaceutical industry upgrades with national economic structure optimization, driving high-quality industry development [2][3] Innovation in Pharmaceuticals - During the "14th Five-Year Plan," China approved 210 innovative drugs and 269 innovative medical devices, with the biopharmaceutical market becoming the second largest globally, accounting for approximately 30% of global innovative drugs in development [1][2] - The approval of innovative drugs has accelerated, with 43 drugs approved in the first half of 2024, marking a 59% year-on-year increase [5][6] Medical Device Sector - From 2014 to 2024, 315 innovative medical devices were approved, with 65 approved in 2024 alone, indicating a sustained high level of approvals [6][7] - The government has introduced measures to support the development of high-end medical devices, including optimizing approval processes and enhancing regulatory frameworks [6][7] Public Health and Disease Control - The article highlights the importance of strengthening public health capabilities and disease control systems, particularly in managing major infectious and chronic diseases [9][10] - The "15th Five-Year Plan" emphasizes the need for a comprehensive approach to disease prevention and control, integrating various health services [9][10] Challenges and Recommendations - Experts suggest increasing funding for innovative drug research and improving the investment environment for pharmaceutical companies [7][8] - The need for enhanced collaboration between healthcare, insurance, and pharmaceutical sectors is emphasized to create a more efficient healthcare delivery system [3][4]